Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our “sample-in, result-out” Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. Our focus on food safety Roka delivers accurate and reliable test results for food pathogens regardless of sample type. You can be confident in the accuracy of your results, the efficiency of our automated system, and our commitment to you and the food safety industry. Roka is here to partner with food manufacturers and help them reach the next level of food safety testing.
Company Growth (employees)
Warren, US
Size (employees)
90 (est)
Roka Bioscience was founded in 2009 and is headquartered in Warren, US

Key People at Roka Bioscience

Paul G. Thomas

Paul G. Thomas

Founder , CEO & Board Member
David R. Patterson

David R. Patterson

Vice President of Manufacturing Operations
Wally Narajowski

Wally Narajowski

Senior Vice President / General Manager
Lars Boesgaard

Lars Boesgaard

Vice President of Finance

Roka Bioscience Office Locations

Roka Bioscience has an office in Warren
Warren, US (HQ)
20 Independence Boulevard

Roka Bioscience Metrics

Roka Bioscience Financial Metrics

Revenue (2016)

$7.2 m

Revenue growth (2015-16), %


Gross profit

($732 k)

Gross profit margin (2016), %


Net income (2016)

($30.8 m)

Market capitalization (28-Apr-2017)

$19.3 m

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$8.8 m
Roka Bioscience's current market capitalization is $19.3 m.
Roka Bioscience's revenue was reported to be $7.2 m in FY, 2016 which is a 21% increase from the previous period.
FY, 2014FY, 2015FY, 2016


$5.1 m$6 m$7.2 m

Revenue growth, %


Cost of goods sold

$8 m

Gross profit

($732 k)

Gross profit Margin, %


R&D expense

$7.3 m

General and administrative expense

$17.7 m

Operating expense total

$36.6 m$41.3 m$36.7 m


($31.6 m)($35.3 m)($29.5 m)

EBIT margin, %


Interest expense

($1.6 m)

Interest income

($1.6 m)

Pre tax profit

($31 m)

Income tax expense

($245 k)

Net Income

($32.2 m)($36.6 m)($30.8 m)
FY, 2014FY, 2015FY, 2016


$7.5 m$3.4 m$8.8 m


$1.3 m$1.8 m

Current Assets

$51.4 m$42.1 m$35.1 m


$12.2 m$9.8 m$7.8 m


$360 k

Total Assets

$103.8 m$74.6 m$61.8 m

Current Liabilities

$13.9 m$18.6 m$15.1 m

Additional Paid-in Capital

$212.1 m$214.6 m$245.1 m

Retained Earnings

($133 m)($169.6 m)($208.1 m)

Total Equity

$36.9 m

Financial Leverage

1.7 x
FY, 2014FY, 2015FY, 2016

Net Income

($32.2 m)($36.6 m)($30.8 m)

Depreciation and Amortization

$4.2 m$6.2 m$5.8 m

Accounts Receivable

$65.5 m


($1.8 m)$9.7 m$5.2 m

Accounts Payable

($3.4 m)

Cash From Operating Activities

($25.2 m)($4.1 m)($22.8 m)

Purchases of PP&E

($171 k)($277 k)

Cash From Investing Activities

($60.5 m)$20.1 m$12.4 m

Cash From Financing Activities

$58.7 m($393 k)$15.8 m

Interest Paid

$688 k$647 k$553 k

Roka Bioscience Market Value History

Roka Bioscience Online Presence

Roka Bioscience News

Roka Bioscience Company Life

You may also be interested in